RARENasdaqPharmaceutical PreparationsFiscal year ends December 31
Ultragenyx Pharmaceutical Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$15.07+0.53 (+3.65%)
Close on Oct 19, 2026
- Market cap
- $1.54B
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2011 to 2025
Gross margin
–
Operating margin
-79.5%+42.3 pts over 5 years
Net margin
-85.4%−16.6 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +20.2% | +22.8% | +19.9% | – |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | -48.9% | -20.6% | -657.1% | |
| Return on assets | -44.7% | -12.9% | -37.9% | |
| Current ratio | 6.67 | 6.83 | 2.48 | |
| Capex to revenue | 7660.2% | 16.2% | 0.9% | |
| Diluted shares | 40M | 61M | 99M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Ultragenyx Pharmaceutical generated $2.07B from operations and spent $246.22M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$2.07B
Used
$246.22M
Capital expenditure$246.22M100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-85.4%
×Asset turnover0.44×
×Equity multiplier17.34×
=Return on equity, FY2025-657.1%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -85.4% | 0.44× | 17.34× | -657.1% |
| FY2024 | -101.6% | 0.37× | 5.65× | -214.7% |
| FY2023 | -139.9% | 0.29× | 4.84× | -193.6% |
| FY2022 | -194.7% | 0.24× | 2.41× | -111.0% |
| FY2021 | -129.2% | 0.21× | 1.58× | -43.7% |
| FY2020 | -68.8% | 0.19× | 1.60× | -20.6% |
| FY2019 | -388.3% | 0.11× | 1.47× | -63.8% |
| FY2018 | -383.7% | 0.09× | 1.22× | -39.8% |
| FY2017 | -11567.3% | 0.01× | 1.20× | -70.5% |
| FY2016 | -184867.7% | 0.00× | 1.09× | -48.9% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
3of 7 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$575.00M
- Cash generatingOperating cash flow above zero-$466.00M
- Return on assets improvedROA up on the prior year-38.2% → -38.3%
- Earnings backed by cashOperating cash flow above net income-$466.00M vs -$575.00M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose2.38 → 2.48
- No dilutionShare count did not rise91M → 99M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose0.38 → 0.45